Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting

ConferenceMOGENRY®MCO-010Positive

AI Analysis

Summary

Nanoscope Therapeutics will present updates on MOGENRY® and four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 at Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting.

Clinical Trial Data

Phase

Phase 2b/3

Importance:4/10

Sentiment:

0.30

OphthalmologyRetinal TherapiesClinical Trial UpdateConference PresentationDrug Delivery

Related Companies

$AHR $MDCE

Read the original article

Published by PR Newswire Clinical Trials on October 6, 2026 11:02 AM

Read Original